Curcumin combined with FAPαc vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-α in melanoma

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25932-25942

  Jiang, Guan Min ^a   Xie, Wan Ying ^b   Wang, Hong Sheng ^c   Du, Jun ^c   Wu, Bai Ping ^b   Xu, Wei ^b   Liu, Hui Fang ^b   Xiao, Ping ^a   Liu, Zhi Gang ^a   Li, Hong Yan ^a   Liu, Shuang Quan ^b   Yin, Wen Jun ^b   Zhang, Qiu Gui ^b   Liang, Jian Ping ^a   Huang, Hong Jun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Curcumin; Fibroblast activation protein ; Immunotherapy; Indolamine 2,3 dioxygenase; Melanoma

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CURCUMIN; DIPEPTIDYL PEPTIDASE; EPITOPE; FIBROBLAST ACTIVATION PROTEIN A VACCINE; INDOLEAMINE 2,3 DIOXYGENASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CPG ODN 1826; GELATINASE; MEMBRANE PROTEIN; OLIGODEOXYRIBONUCLEOTIDE; SEPRASE; SERINE PROTEINASE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CATALYSIS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MELANOMA; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; SURVIVAL RATE; TH1 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CANCER VACCINES; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GELATINASES; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; SERINE ENDOPEPTIDASES; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84944463730     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4577     Document Type: Article

References (33)

1. Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Human vaccines & immunotherapeutics. 2014; 10:3111-3116.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010; 363:711-723.
3. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature reviews Immunology. 2004; 4:762-774.
4. Takikawa O. Biochemical and medical aspects of the indoleamine 2, 3-dioxygenase-initiated L-tryptophan metabolism. Biochemical and biophysical research communications. 2005; 338:12-19.
5. Jiang GM, He YW, Fang R, Zhang G, Zeng J, Yi YM, Zhang S, Bu XZ, Cai SH, Du J. Sodium butyrate downregulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels. The international journal of biochemistry & cell biology. 2010; 42:1840-1846.
6. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nature medicine. 2003; 9:1269-1274.
7. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer research. 2007; 67:792-801.
8. Ohshio Y, Teramoto K, Hanaoka J, Tezuka N, Itoh Y, Asai T, Daigo Y, Ogasawara K. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. Cancer science. 2015; 106:134-142.
9. Kelly T, Huang Y, Simms AE, Mazur A. Fibroblast activation protein-alpha: a key modulator of the microenvironment in multiple pathologies. International review of cell and molecular biology. 2012; 297:83-116.
10. Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR, Old LJ. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proceedings of the National Academy of Sciences of the United States of America. 1988; 85:3110-3114.
11. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clinical cancer research 2003; 9:1639-1647.
12. Jackson RC. Contributions of protein structure-based drug design to cancer chemotherapy. Seminars in oncology. 1997; 24:164-172.
13. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010; 330:827-830.
14. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. The Journal of clinical investigation. 2007; 117:1147-1154.
15. Yu L, Mu Y, Sa N, Wang H, Xu W. Tumor necrosis factor alpha induces epithelial-mesenchymal transition and promotes metastasis via NF-kappaB signaling pathwaymediated TWIST expression in hypopharyngeal cancer. Oncology reports. 2014; 31:321-327.
16. Wang H, Fang R, Wang XF, Zhang F, Chen DY, Zhou B, Wang HS, Cai SH, Du J. Stabilization of Snail through AKT/GSK-3beta signaling pathway is required for TNFalpha-induced epithelial-mesenchymal transition in prostate cancer PC3 cells. European journal of pharmacology. 2013; 714:48-55.
17. Xue C, Plieth D, Venkov C, Xu C, Neilson EG. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer research. 2003; 63:3386-3394.
18. Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, Wang H, Cai SH, Du J. Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochimica et biophysica acta. 2013; 1833:663-671.
19. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life sciences. 2006; 78:2081-2087.
20. Yao QY, Xu BL, Wang JY, Liu HC, Zhang SC, Tu CT. Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC complementary and alternative medicine. 2012; 12:156.
21. Zeng J, Cai S, Yi Y, He Y, Wang Z, Jiang G, Li X, Du J. Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2, 3-dioxygenase inhibitor 1-methyl tryptophan. Cancer research. 2009; 69:3963-3970.
22. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Frontiers in oncology. 2014; 4:385.
23. Gilboa E. The promise of cancer vaccines. Nature reviews Cancer. 2004; 4:401-411.
24. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer cell. 2010; 17:135-147.
25. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87:7235-7239.
26. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer research. 2005; 65:11156-11163.
27. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. The Journal of clinical investigation. 2006; 116:1955-1962.
28. Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ, Rettig WJ, Schnapp A. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. International journal of cancer 1997; 71:383-389.
29. Kelderman S, Schumacher TN, Haanen JB. Acquired and intrinsic resistance in cancer immunotherapy. Molecular oncology. 2014; 8:1132-1139.
30. Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. The Journal of dermatological treatment. 2014; 25:401-408.
31. Jeong YI, Kim SW, Jung ID, Lee JS, Chang JH, Lee CM, Chun SH, Yoon MS, Kim GT, Ryu SW, Kim JS, Shin YK, Lee WS, Shin HK, Lee JD, Park YM. Curcumin suppresses the induction of indoleamine 2, 3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. The Journal of biological chemistry. 2009; 284:3700-3708.
32. Huang T, Chen Z, Fang L. Curcumin inhibits LPS-induced EMT through downregulation of NF-kappaB-Snail signaling in breast cancer cells. Oncology reports. 2013; 29:117-124.
33. Yu L, Mu Y, Sa N, Wang H, Xu W. Tumor necrosis factor alpha induces epithelial-mesenchymal transition and promotes metastasis via NF-kappaB signaling pathwaymediated TWIST expression in hypopharyngeal cancer. Oncology reports. 2014; 31:321-327.